Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

Abazyan, 2010, Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology, Biol. Psychiatry, 68, 1172, 10.1016/j.biopsych.2010.09.022 Abbas, 2009, Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo, Psychopharmacology, 205, 119, 10.1007/s00213-009-1521-8 Abel, 2003, Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study, Neuroreport, 14, 387, 10.1097/00001756-200303030-00018 Adolphs, 2009, The social brain: neural basis of social knowledge, Annu. Rev. Psychol., 60, 693, 10.1146/annurev.psych.60.110707.163514 Agarwal, 2013, Transcranial direct current stimulation in schizophrenia, Clin. Psychopharmacol. Neurosci., 11, 118, 10.9758/cpn.2013.11.3.118 Ahn, 2011, The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study, Hum. Psychopharmacol., 26, 568, 10.1002/hup.1246 Alberati, 2012, Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia, Neuropharmacology, 62, 1152, 10.1016/j.neuropharm.2011.11.008 Alex, 2007, Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission, Pharmacol. Ther., 113, 296, 10.1016/j.pharmthera.2006.08.004 Alexander, 2012, Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the α7 positive modulator galantamine, Psychopharmacology, 220, 627, 10.1007/s00213-011-2539-2 Almeida, 2013, Cannabidiol exhibits anxiolytic but not antipsychotic properties evaluated in the social interaction test, Prog. Neuropsychopharmacol. Biol. Psychiatry, 41, 30, 10.1016/j.pnpbp.2012.10.024 Andreasen, 1982, Negative symptoms in schizophrenia. Definition and reliability, Arch. Gen. Psychiatry, 39, 784, 10.1001/archpsyc.1982.04290070020005 Andreasen, 1989, The scale for the assessment of negative symptoms (SANS): conceptual and theroretical foundations, Br. J. Psychiatry, S7, 238 Andreassen, O.A., Harbo, H.F., Wang, Y., Thompson, W.K., Schork, A.J., Mattingsdal, M., Zuber, V., Bettella, F., Ripke, S., Kelsoe, J.R., Kendler, K.S., O’Donovan, M.C., Sklar, P., Psychiatric Genomics Consortium (PGC) Bipolar Disorder Schizophrenia Work Groups. International Multiple Sclerosis Genetics Consortium (IMSGC), McEvoy, L.K., Desikan, R.S., Lie, B.A., Djurovic, S., Dale, A.M., 2014. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol. Psychiatry, 10.1038/mp.2013.195 Arango, 2013, Pharmacological approaches to treating negative symptoms: a review of clinical trials, Schizophr. Res., 150, 346, 10.1016/j.schres.2013.07.026 Archer, 2010, Neurodegeneration in schizophrenia, Expert Rev. Neurother., 10, 1131, 10.1586/ern.09.152 Asenjo-Lobos, 2010, Clozapine versus other atypical antipsychotics for schizophrenia, Cochrane Database Syst. Rev., CD006633 Baaré, 1999, Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology, Biol. Psychiatry, 45, 1597, 10.1016/S0006-3223(98)00266-2 Baharnoori, 2012, Neonatal behavioral changes in rats with gestational exposure to lipopolysaccharide: a prenatal infection model for developmental neuropsychiatric disorders, Schizophr. Bull., 38, 444, 10.1093/schbul/sbq098 Baird, 2008, Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption, Pharmacol. Biochem. Behav., 88, 272, 10.1016/j.pbb.2007.08.011 Baker, 2005, Adolescents and young adults with 22q11 deletion syndrome: psychopathology in an at-risk group, Br. J. Psychiatry, 186, 115, 10.1192/bjp.186.2.115 Balla, 2012, Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia, Eur. Neuropsychopharmacol., 22, 902, 10.1016/j.euroneuro.2012.03.006 Barch, 2013, Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5, Schizophr. Res., 150, 15, 10.1016/j.schres.2013.04.027 Barch, 2010, Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions, Schizophr. Bull., 36, 919, 10.1093/schbul/sbq068 Bardgett, 2009, Dopamine modulates effort-based decision making in rats, Behav. Neurosci., 123, 242, 10.1037/a0014625 Barr, 2012, A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia, Brain Stimul., 5, 337, 10.1016/j.brs.2011.06.003 Barnes, 2014, Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia, Eur. Neuropsychopharmacol., 24, 744, 10.1016/j.euroneuro.2013.10.001 Barsaglini, A., Sartori, G., Benetti, S., Pettersson-Yeo,W., Mechelli, A., 2014. The effects of psychotherapy on brain function: a systematic and critical review. Progr. Neurobiol. 10.1016/j.pneurobio.2013.10.006 Beck, 2013, Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia, Schizophr. Bull., 39, 43, 10.1093/schbul/sbr040 Behere, 2013, Dorsolateral prefrontal lobe volume and neurological soft signs as predictors of clinical social and functional outcome in schizophrenia: a longitudinal study, Indian J. Psychiatry, 55, 111, 10.4103/0019-5545.111445 Benoit, 2012, The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: a voxel-based morphometry study, Front. Psychiatry, 3, 42, 10.3389/fpsyt.2012.00042 Bergé, 2011, Gray matter volume deficits and correlation with insight and negative symptoms in first-psychotic-episode subjects, Acta Psychiatr. Scand., 123, 431, 10.1111/j.1600-0447.2010.01635.x Berlim, 2013, Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials, J. Psychiatr. Res., 47, 1, 10.1016/j.jpsychires.2012.09.025 Berridge, 2013, Neuroscience of affect: brain mechanisms of pleasure and displeasure, Curr. Opin. Neurobiol., 23, 294, 10.1016/j.conb.2013.01.017 Berridge, 2009, Dissecting components of reward: liking, wanting, and learning, Curr. Opin. Pharmacol., 9, 65, 10.1016/j.coph.2008.12.014 Bertrand, 2010, Longitudinal MRI monitoring of brain damage in the neonatal ventral hippocampal lesion rat model of schizophrenia, Hippocampus, 20, 264 Bio, 2011, Vocational rehabilitation improves cognition and negative symptoms in schizophrenia, Schizophr. Res., 126, 265, 10.1016/j.schres.2010.08.003 Blanchard, 2006, The structure of negative symptoms within schizophrenia: implications for assessment, Schizophr. Bull., 32, 238, 10.1093/schbul/sbj013 Blanchard, 2011, Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia, Schizophr. Bull., 37, 291, 10.1093/schbul/sbq104 Bliksted, 2014, Social cognition and neurocognitive deficits in first-episode schizophrenia, Schizophr. Res., 153, 9, 10.1016/j.schres.2014.01.010 Bluhm, 2007, Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network, Schizophr. Bull., 33, 1004, 10.1093/schbul/sbm052 Boonstra, 2012, Duration of untreated psychosis and negative symptoms – a systematic review and meta-analysis of individual patient data, Schizophr. Res., 142, 12, 10.1016/j.schres.2012.08.017 Bor, 2011, How can cognitive remediation therapy modulate brain activation in schizophrenia? An fMRI study, Psychiatry Res., 192, 160, 10.1016/j.pscychresns.2010.12.004 Bora, 2009, Theory of mind impairment in schizophrenia: meta-analysis, Schizophr. Res., 109, 1, 10.1016/j.schres.2008.12.020 Bottlender, 2003, Negative symptoms in depressed and schizophrenic patients: how do they differ?, J. Clin. Psychiatry, 64, 954, 10.4088/JCP.v64n0816 Botvinick, 2009, Effort discounting in human nucleus accumbens, Cogn. Affect. Behav. Neurosci., 9, 16, 10.3758/CABN.9.1.16 Boulay, 2004, SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats, Neuropharmacology, 46, 1121, 10.1016/j.neuropharm.2004.02.008 Boutros, 2013, Negative symptoms in schizophrenia: a comprehensive review of electrophysiological investigations, Clin. Schizophr. Relat. Psychos., 21, 1 Bracht, 2014, While matter pathway organization of the reward system is related to positive and negative symptoms in schizophrenia, Schizophr. Res., 153, 136, 10.1016/j.schres.2014.01.015 Brady, 2008, Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia, Psychopharmacology, 200, 205, 10.1007/s00213-008-1195-7 Bressan, 2003, Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123l]epidepride SPECT study of amisulpride-treated patients, Am. J. Psychiatry, 160, 1413, 10.1176/appi.ajp.160.8.1413 Broberg, 2013, A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by magnetic resonance imaging, Behav. Brain Res., 250, 1, 10.1016/j.bbr.2013.04.026 Brosda, 2014, α2-adrenoceptors are targets for antipsychotic drugs, Psychopharmacology, 231, 801, 10.1007/s00213-014-3459-8 Brown, 2012, Potential therapeutic avenues to tackle social cognition problems in schizophrenia, Expert Rev. Neurother., 12, 71, 10.1586/ern.11.183 Broyd, 2009, Default-mode brain dysfunction in mental disorders: a systematic review, Neurosci. Biobehav. Rev., 33, 279, 10.1016/j.neubiorev.2008.09.002 Brüne, 2005, “Theory of mind” in schizophrenia: a review of the literature, Schizophr. Bull., 31, 21, 10.1093/schbul/sbi002 Brunelin, 2012, Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia, Am. J. Psychiatry, 169, 719, 10.1176/appi.ajp.2012.11071091 Buchanan, 2007, Persistent negative symptoms in schizophrenia: an overview, Schizophr. Bull., 33, 1013, 10.1093/schbul/sbl057 Buchanan, 2011, A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia, Biol. Psychiatry, 69, 442, 10.1016/j.biopsych.2010.09.052 Buchanan, 2011, The FDA-NIMH-MATRICS guideline for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?, Schizophr. Bull., 37, 1209, 10.1093/schbul/sbq038 Buchanan, 2010, The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements, Schizophr. Bull., 36, 71, 10.1093/schbul/sbp116 Buchanan, 2012, Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia, J. Clin. Psychopharmacol., 32, 36, 10.1097/JCP.0b013e31823f880a Burbridge, 2007, Anhedonia and the experience of emotion in individuals with schizophrenia, J. Abnorm. Psychol., 116, 30, 10.1037/0021-843X.116.1.30 Burket, 2013, d-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling, Brain Res. Bull., 96, 62, 10.1016/j.brainresbull.2013.05.003 Burket, 2014, Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders, Brain Res. Bull., 100, 70, 10.1016/j.brainresbull.2013.11.005 Byrne, 2010, Primate social cognition: uniquely primate, uniquely social, or just unique?, Neuron, 65, 815, 10.1016/j.neuron.2010.03.010 Carpenter, 1999, Deficit psychopathology and a paradigm shift in schizophrenia research, Biol. Psychiatry, 46, 352, 10.1016/S0006-3223(99)00088-8 Carpenter, 1988, Deficit and nondeficit forms of schizophrenia: the concept, Am. J. Psychiatry, 145, 5878 Carrington, 2009, Are there theory of mind regions in the brain? A review of the neuroimaging literature, Hum. Brain Mapp., 30, 2313, 10.1002/hbm.20671 Carter, 2007, Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative, Schizophr. Bull., 33, 1131, 10.1093/schbul/sbm081 Cascella, 2010, Gray-matter abnormalities in deficit schizophrenia, Schizophr. Res., 120, 63, 10.1016/j.schres.2010.03.039 Castagné, 2009, Preclinical behavioral models for predicting antipsychotic activity, Adv. Pharmacol., 57, 89 Ceccarini, 2013, Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia, Neuroimage, 79, 304, 10.1016/j.neuroimage.2013.04.052 Chartoff, 2012, Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats, Neuropharmacology, 62, 167, 10.1016/j.neuropharm.2011.06.014 Chase, 2011, Apathy in neuropsychiatry disease: diagnosis, pathophysiology, and treatment, Neurotox. Res., 19, 266, 10.1007/s12640-010-9196-9 Chertkow, 2009, Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia, J. Neural Transm., 116, 1529, 10.1007/s00702-009-0255-4 Chin, 2011, Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia, Synapse, 65, 393, 10.1002/syn.20857 Chou, 2012, Towards medication-enhancement of cognitive interventions in schizophrenia, Handb. Exp. Pharmacol., 213, 81, 10.1007/978-3-642-25758-2_4 Churchland, 2012, Modulating social behavior with oxytocin: how does it work? What does it mean?, Horm. Behav., 61, 392, 10.1016/j.yhbeh.2011.12.003 Citrome, 2013, A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach, CNS Drugs, 27, 879, 10.1007/s40263-013-0105-7 Clifton, 2013, Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine, Psychopharmacology, 225, 579, 10.1007/s00213-012-2845-3 Cohen, 2007, Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date, Schizophr. Bull., 33, 1201, 10.1093/schbul/sbl066 Collier, 2013, The utility of the zebrafish model in conditioned place preference to assess the rewarding effects of drugs, Behav. Pharmacol., 24, 375, 10.1097/FBP.0b013e328363d14a Corcoran, 2011, The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis, Psychol. Med., 41, 251, 10.1017/S0033291710000802 Coulston, 2011, Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use, Schizophr. Res. Treat., 2011, 501726 Coyle, 2012, Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications, Handb. Exp. Pharmacol., 213, 267, 10.1007/978-3-642-25758-2_10 Croxson, 2009, Effort-based cost-benefit valuation and the human brain, J. Neurosci., 29, 4531, 10.1523/JNEUROSCI.4515-08.2009 Cuijpers, 2013, Does cognitive behavior therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis, BMJ Open, 3, e002542, 10.1136/bmjopen-2012-002542 Cuthbert, 2014, The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology, World Psychiatry, 13, 28, 10.1002/wps.20087 Davis, 2013, Effects of single dose intranasal oxytocin on social cognition in schizophrenia, Schizophr. Res., 147, 393, 10.1016/j.schres.2013.04.023 Davis, 2014, Psychopharmacology of the negative symptoms: Current status and prospects for progress, Eur. Neuropsychopharmacol., 24, 788, 10.1016/j.euroneuro.2013.10.010 Dean, 2012, Minocycline: therapeutic potential in psychiatry, CNS Drugs, 26, 391, 10.2165/11632000-000000000-00000 De Bartolomeis, 2012, Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia, Eur. J. Pharmacol., 682, 1, 10.1016/j.ejphar.2012.02.033 De Berardis, 2013, The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review, CNS Neurol. Disord. Drug Targets, 12, 252, 10.2174/1871527311312020012 Dekeyne, 2000, Citalopram reduces social interaction in rats by activation of serotonin 5-HT2C receptors, Neuropharmacology, 39, 1114, 10.1016/S0028-3908(99)00268-3 Dekeyne, 2008, S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models, Psychopharmacology, 199, 549, 10.1007/s00213-008-1177-9 Demjaha, 2012, Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis, Schizophr. Bull., 38, 351, 10.1093/schbul/sbq088 Der-Avakian, 2012, The neurobiology of anhedonia and other reward-related deficits, Trends Neurosci., 35, 68, 10.1016/j.tins.2011.11.005 Desbonnet, 2012, Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene×environment interaction, Brain Behav. Immun., 26, 660, 10.1016/j.bbi.2012.02.010 Deserno, 2013, Reinforcement learning and dopamine in schizophrenia: dimensions of symptoms or specific features of a disease group?, Front. Psychiatry, 4, 172, 10.3389/fpsyt.2013.00172 Diekhof, 2012, The role of the human ventral striatum and the medial orbifrontal cortex in the representation of reward magnitude – an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing, Neuropsychologia, 50, 1252, 10.1016/j.neuropsychologia.2012.02.007 Dixon, 2010, The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements, Schizophr. Bull., 36, 48, 10.1093/schbul/sbp115 Dodero, 2013, Neuroimaging evidence of major morpho-anatomical and functional abnormalities in the BTBR T+TF/J mouse model of autism, PLoS One, 8, e76655, 10.1371/journal.pone.0076655 Dold, 2013, Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials, Eur. Neuropsychopharmacol., 23, 1023, 10.1016/j.euroneuro.2013.03.001 Dölen, 2013, Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin, Nature, 501, 179, 10.1038/nature12518 Doty, 2007, Alkmaion׳s discovery that brain creates mind: a revolution in human knowledge comparable to that of Copernicus and of Darwin, Neuroscience, 147, 561, 10.1016/j.neuroscience.2007.02.046 Dowd, 2010, Anhedonia and emotional experience in schizophrenia: neural and behavioral indicators, Biol. Psychiatry, 67, 902, 10.1016/j.biopsych.2009.10.020 Dowd, 2012, Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia, PLoS One, 7, e35622, 10.1371/journal.pone.0035622 Drew, 2007, Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing, J. Neurosci., 27, 7731, 10.1523/JNEUROSCI.1736-07.2007 Dunbar, 2010, The social role of touch in humans and primates: behavioural function and neurobiological mechanisms, Neurosci. Biobehav. Rev., 34, 260, 10.1016/j.neubiorev.2008.07.001 Ehrlich, 2012, Striatal function in relation to negative symptoms in schizophrenia, Psychol. Med., 42, 267, 10.1017/S003329171100119X Elis, 2013, Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions, Clin. Psychol. Rev., 2013, 914, 10.1016/j.cpr.2013.07.001 Ellegood, 2013, Neuroanatomical analysis of the BTBR mouse model of autism using magnetic resonance imaging and diffusion tensor imaging, Neuroimage, 70, 288, 10.1016/j.neuroimage.2012.12.029 Fahim, 2005, Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study, Psychiatry Res., 140, 1, 10.1016/j.pscychresns.2005.06.003 Fanning, 2012, Is it possible to have impaired neurocognition but good social cognition in schizophrenia?, Schizophr. Res., 135, 68, 10.1016/j.schres.2011.12.009 Fatemi, 2009, The neurodevelopmental hypothesis of schizophrenia, revisited, Schizophr. Bull., 35, 528, 10.1093/schbul/sbn187 Feifel, 2010, Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients, Biol. Psychiatry, 68, 678, 10.1016/j.biopsych.2010.04.039 Ferraris, 2011, Recent advances in the discovery of d-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia, Curr. Pharm. Des., 17, 103, 10.2174/138161211795049633 Fervaha, 2013, Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-marking, J. Psychiatr. Res., 47, 1590, 10.1016/j.jpsychires.2013.08.003 Filippi, 2014, Patterns of brain structural changes in first-contact, antipsychotic drug-naïve patients with schizophrenia, Am. J. Neuroradiol., 35, 30, 10.3174/ajnr.A3583 Fischer, 2012, Cortical structural abnormalities in deficit versus nondeficit schizophrenia, Schizophr. Res., 136, 51, 10.1016/j.schres.2012.01.030 Fischer-Shoffy, 2013, Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls, Front. Neurosci., 7, 127 Fitch, 2010, Social cognition and the evolution of language: constructing cognitive phylogenies, Neuron, 65, 795, 10.1016/j.neuron.2010.03.011 Fone, 2008, Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders, Neurosci. Biobehav. Rev., 32, 1087, 10.1016/j.neubiorev.2008.03.003 Fossat, 2012, Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex, Cereb. Cortex., 22, 595, 10.1093/cercor/bhr130 Foussias, 2014, Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders, Eur. Neuropsychopharmacol., 24, 693, 10.1016/j.euroneuro.2013.10.017 Franberg, 2012, Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow, Synapse, 66, 650, 10.1002/syn.21551 Frith, 2012, Mechanisms of social cognition, Annu. Rev. Psychol., 63, 287, 10.1146/annurev-psych-120710-100449 Fulford, 2013, Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms, Schizophr. Res., 147, 125, 10.1016/j.schres.2013.03.024 Fusar-Poli, 2013, The psychosis high-risk state: a comprehensive state-of-the-art review, JAMA Psychiatry, 70, 107, 10.1001/jamapsychiatry.2013.269 Fusar-Poli, 2014, Attenuated psychosis syndrome: ready for DSM-5.1?, Annu. Rev. Clin. Psychol., 10, 24.1, 10.1146/annurev-clinpsy-032813-153645 Fusar-Poli, 2012, Neuroanatomical maps of psychotis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies, Schizophr. Bull., 38, 1297, 10.1093/schbul/sbr134 Fusar-Poli, 2013, Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies, Neurosci. Biobehav. Rev., 37, 1680, 10.1016/j.neubiorev.2013.06.001 Galderisi, 2008, Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia, Schizophr. Bull., 34, 393, 10.1093/schbul/sbm097 Gandal, 2012, GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction, Transl. Psychiatry, 2, e142, 10.1038/tp.2012.69 Gard, 2007, Anhedonia in schizophrenia: distinction between anticipatory and consummatory pleasure, Schizophr. Res., 93, 253, 10.1016/j.schres.2007.03.008 Ghods-Sharifi, 2010, Differential effects on effort discounting induced by inactivation of the nucleus accumbens core or shell, Behav. Neurosci., 124, 179, 10.1037/a0018932 Gil-da-Costa, 2013, Nonhuman primate model of schizophrenia using a noninvasive EEG method, Proc. Natl. Acad. Sci. USA, 110, 15425, 10.1073/pnas.1312264110 Gillies, 2013, Benzodiazepines for psychosis-induced aggression or agitation, Cochrane Database Syst. Rev., 9, CD003079 Gilmour, 2012, NMDA receptors, cognition and schizophrenia – testing the validity of the NMDA receptor hypofunction hypothesis, Neuropharmacology, 62, 1401, 10.1016/j.neuropharm.2011.03.015 Gobert, 2011, Simultaneous quantification of d- vs l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents, J. Neurosci. Methods, 202, 143, 10.1016/j.jneumeth.2011.08.040 Goghari, 2010, The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question, Neurosci. Biobehav. Rev., 34, 468, 10.1016/j.neubiorev.2009.09.004 Gold, 2013, Negative symptoms of schizophrenia are associated with abnormal effort-cost computations, Biol. Psychiatry, 74, 130, 10.1016/j.biopsych.2012.12.022 Goodson, 2010, Nonapeptide mechanisms of social cognition, behavior and species-specific social systems, Curr. Opin. Neurobiol., 20, 784, 10.1016/j.conb.2010.08.020 Gordon, 2011, Oxytocin and social motivation, Dev. Cogn. Neurosci., 1, 471, 10.1016/j.dcn.2011.07.007 Gradin, 2011, Expected value and prediction error abnormalities in depression and schizophrenia, Brain, 134, 1751, 10.1093/brain/awr059 Gradin, 2013, Salience network-midbrain dysconnectivity and blunted reward signals in schizophrenia, Psychiatry Res., 211, 104, 10.1016/j.pscychresns.2012.06.003 Grant, 2012, Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia, Arch. Gen. Psychiatry, 69, 121, 10.1001/archgenpsychiatry.2011.129 Green, 2012, Social cognition in schizophrenia, Part 1: performance across phase of illness, Schizophr. Bull., 38, 854, 10.1093/schbul/sbq171 Green, 2008, Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities, Schizophr. Bull., 34, 1211, 10.1093/schbul/sbm145 Gross, 2013, Dopamine D3 receptor antagonism – still a therapeutic option for the treatment of schizophrenia, Naunyn Schmiedebergs Arch. Pharmacol., 386, 155, 10.1007/s00210-012-0806-3 Guo, 2014, Key functional circuitry altered in schizophrenia involves parietal regions associated with sense of self, Hum. Brain Mapp., 35, 123, 10.1002/hbm.22162 Gur, 2007, Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia, Arch. Gen. Psychiatry, 64, 1356, 10.1001/archpsyc.64.12.1356 Gururajan, 2010, Current pharmacological models of social withdrawal in rats: relevance to schizophrenia, Behav. Pharmacol., 21, 690, 10.1097/FBP.0b013e32833fa7df Halene, 2009, Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia, Genes Brain Behav., 8, 661, 10.1111/j.1601-183X.2009.00504.x Hanks, 2013, Pharmacological disruption of mouse social approach behavior: relevance to negative symptoms of schizophrenia, Behav. Brain Res., 252, 405, 10.1016/j.bbr.2013.06.017 Hanson, 2010, Assessment of pharmacotherapy for negative symptoms of schizophrenia, Curr. Psychiatry Rep., 12, 563, 10.1007/s11920-010-0148-0 Harper, 2012, Alterations of social interaction through genetic and environmental manipulation of the 22q11.2 gene Sept5 in the mouse brain, Hum. Mol. Genet., 21, 3489, 10.1093/hmg/dds180 Hartling, 2012, Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis, Ann. Intern. Med., 157, 498, 10.7326/0003-4819-157-7-201210020-00525 Harvey, 2006, Negative symptoms and cognitive deficits: what is the nature of their relationship?, Schizophr. Bull., 32, 250, 10.1093/schbul/sbj011 Harvey, 2009, Relation between emotional face memory and social anhedonia in schizophrenia, J. Psychiatry Neurosci., 34, 102 Hashimoto, 2013, Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders, Eur. Arch. Psychiatry Clin. Neurosci., 263, 367, 10.1007/s00406-013-0399-y Hastrup, 2013, Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study), Br. J. Psychiatry, 202, 35, 10.1192/bjp.bp.112.112300 Haut, 2010, Prefrontal cortical changes following: cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity, Neuropsychopharmacology, 35, 1850, 10.1038/npp.2010.52 Heckers, 2011, Bleuler and the neurobiology of schizophrenia, Schizophr. Bull., 37, 1131, 10.1093/schbul/sbr108 Heckers, 2013, Structure of the psychotic disorders classification in DSM-5, Schizophr. Res., 150, 13, 10.1016/j.schres.2013.04.039 Hedlund, 2009, The 5-HT7 receptor and disorders of the nervous system: an overview, Psychopharmacology, 206, 345, 10.1007/s00213-009-1626-0 Heidbreder, 2010, Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders, Ann. NY Acad. Sci., 1187, 4, 10.1111/j.1749-6632.2009.05149.x Hida, 2013, Behavioral phenotypes in schizophrenic animal models with multiple combinations of genetic and environmental factors, J. Pharmacol. Sci., 121, 185, 10.1254/jphs.12R15CP Hillman, 2012, Neural encoding of competitive effort in the anterior cingulate cortex, Nat. Neurosci., 15, 1290, 10.1038/nn.3187 Hines, 2013, Disrupting the clustering of GABAA receptor α2 subunits in the frontal cortex leads to reduced γ-power and cognitive deficits, Proc. Natl. Acad. Sci. USA, 110, 16628, 10.1073/pnas.1308706110 Hiroi, 2013, Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders, Mol. Psychiatry, 18, 1153, 10.1038/mp.2013.92 Hoe, 2012, The causal relationships between neurocognition, social cognition and functional outcome over time in schizophrenia: a latent difference score approach, Psychol. Med., 42, 2287, 10.1017/S0033291712000578 Hollon, 2006, Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety, Annu. Rev. Psychol., 57, 285, 10.1146/annurev.psych.57.102904.190044 Honey, 2008, Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo, J. Neurosci., 28, 6295, 10.1523/JNEUROSCI.0910-08.2008 Horan, 2011, Development and psychometric validation of the clinical assessment interview for negative symptoms (CAINS), Schizophr. Res., 132, 140, 10.1016/j.schres.2011.06.030 Horan, 2010, Electrophysiological correlates of emotional responding in schizophrenia, J. Abnorm. Psychol., 19, 18, 10.1037/a0017510 Hosking, J.G., Cocker, P.J., Winstanley, C.A., 2014. Dissociable contributions of anterior cingulate cortex and basolateral amygdala on a rodent cost/benefit decision-making task of cognitive effort. Neuropsychopharmacology, 10.1038/npp.2014.27 Hovington, 2012, Identifying persistent negative symptoms in first episode psychosis, BMC Psychiatry, 12, 224, 10.1186/1471-244X-12-224 Hovington, 2012, Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia, Expert Rev. Neurother., 12, 53, 10.1586/ern.11.173 Huang, 2014, Chronic and acute intranasal oxytocin produce divergent social effects in mice, Neuropsychopharmacology, 39, 102, 10.1038/npp.2013.310 Huxley, 2014, The relationship between anhedonia and positive, negative, and general symptomatology in patients with schizophrenia, Issues Ment. Health Nurs., 35, 122, 10.3109/01612840.2013.843222 Jauhar, 2014, Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias, Br. J. Psychiatry, 204, 20, 10.1192/bjp.bp.112.116285 Javitt, 2012, Glycine transport inhibitors in the treatment of schizophrenia, Handb. Exp. Pharmacol., 213, 367, 10.1007/978-3-642-25758-2_12 Jayaram, 2013, Effect of yoga therapy on plasma oxytocin and facial emotion recognition deficits in patients of schizophrenia, Indian J. Psychiatry, 55, S409, 10.4103/0019-5545.116318 Jentsch, 1997, Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat, Neuropsychopharmacology, 17, 92, 10.1016/S0893-133X(97)00034-1 Jo, 2013, Effects of prefrontal cortical inactivation on neural activity in the ventral tegmental area, J. Neurosci., 33, 8159, 10.1523/JNEUROSCI.0118-13.2013 Johnson, 2013, Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness, Proc. Natl. Acad. Sci. USA, 110, 12462, 10.1073/pnas.1307925110 Jones, 2012, Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia, Neuropsychopharmacology, 37, 16, 10.1038/npp.2011.199 Juckel, 2006, Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics, Psychopharmacology, 187, 222, 10.1007/s00213-006-0405-4 Kaiser, 2010, The negative symptoms of schizophrenia: category or continuum?, Psychopathalogy, 44, 345, 10.1159/000325912 Kalkstein, 2010, Neurocognition in schizophrenia, Curr. Top Behav. Neurosci., 4, 373, 10.1007/7854_2010_42 Kamiya, 2012, DISC1 pathway in brain development: exploring therapeutic targets for major psychiatric disorders, Front. Psychiatry, 3, 25 Kanahara, 2013, Orbitofrontal cortex abnormality and deficit schizophrenia, Schizophr. Res., 143, 246, 10.1016/j.schres.2012.11.015 Kantrowitz, 2010, N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?, Brain Res. Bull., 83, 108, 10.1016/j.brainresbull.2010.04.006 Katayama, 2009, Phencyclidine affects firing activity of basolateral amygdala neurons related to social behavior in rats, Neuroscience, 159, 335, 10.1016/j.neuroscience.2009.01.002 Ke, 2010, Bilateral functiona asymmetry disparity in positive and negative schizophrenia revealed by resting-state fMRI, Psychiatry Res., 182, 30, 10.1016/j.pscychresns.2009.11.004 Khodaie-Ardakani, 2014, Pinocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study, Psychiatry Res., 205, 540, 10.1016/j.psychres.2013.12.051 Kim, 2014, Source activation of p300 correlates with negative symptom severity in patients with schizophrenia, Brain Topogr., 27, 307, 10.1007/s10548-013-0306-x Kirkpatrick, 2001, A separate disease within the syndrome of schizophrenia, Arch. Gen. Psychiatry, 58, 165, 10.1001/archpsyc.58.2.165 Kirkpatrick, 2006, The NIMH-MATRICS consensus statement on negative symptoms, Schizophr. Bull., 32, 214, 10.1093/schbul/sbj053 Kirkpatrick, 2011, The brief negative symptom scale: psychometric properties, Schizophr. Bull., 37, 300, 10.1093/schbul/sbq059 Kirsten, 2012, Hypoactivity of the central dopaminergic system and autistic-like behavior induced by a single early prenatal exposure to lipopolysaccharide, J. Neurosci. Res., 90, 1903, 10.1002/jnr.23089 Kirsten, 2010, Prenatal lipopolysaccharide reduces social behavior in male offspring, Neuroimmunomodulation, 17, 240, 10.1159/000290040 Kishi, 2013, Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia, Int. J. Neuropsychopharmacol., 17, 343, 10.1017/S1461145713000667 Kitis, 2012, Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia, Psychiatry Clin. Neurosci., 66, 34, 10.1111/j.1440-1819.2011.02293.x Klingberg, 2012, Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study, J. Nerv. Ment. Dis., 200, 569, 10.1097/NMD.0b013e31825bfa1d Koike, 2009, Behavioral abnormality and pharmacologic response in social isolation-reared mice, Behav. Brain Res., 202, 114, 10.1016/j.bbr.2009.03.028 Koike, 2013, Reduced but broader prefrontal activity in patients with schizophrenia during n-back working memory tasks: a multi-channel near-infrared spectroscopy study, J. Psychiatr. Res., 47, 1240, 10.1016/j.jpsychires.2013.05.009 Konstantakopoulos, 2011, Apathy, cognitive deficits and functional impairment in schizophrenia, Schizophr. Res., 133, 193, 10.1016/j.schres.2011.07.003 Koros, 2007, The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats, Neuropsychopharmacology, 32, 562, 10.1038/sj.npp.1301133 Kreinin, 2014, Adjunctive pregnenolone ameliorates the cognitive deficits in recent-onset schizophrenia, Clin. Schizophr. Relat. Psychos., 10.3371/CSRP.KRBA.013114 Kring, 2014, The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs, Eur. Neuropsychopharmacol., 24, 725, 10.1016/j.euroneuro.2013.06.007 Kring, 2014, Emotion deficits in people with schizophrenia, Annu. Rev. Clin. Psychol., 9, 409, 10.1146/annurev-clinpsy-050212-185538 Kring, 2013, The clinical assessment interview for negative symptoms (CAINS): final development and validation, Am. J. Psychiatry, 170, 165, 10.1176/appi.ajp.2012.12010109 Kringelbach, 2005, The human orbitofrontal cortex: linking reward to hedonic experience, Nat. Rev. Neurosci., 6, 691, 10.1038/nrn1747 Kumari, 2011, Neural changes following cognitive behaviour therapy for psychosis: a longitudinal study, Brain, 134, 2396, 10.1093/brain/awr154 Labrie, 2010, Genetic loss of d-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice, Genes Brain Behav., 9, 11, 10.1111/j.1601-183X.2009.00529.x La Fougère, 2005, D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123l-iodobenzamide SPECT study, J. Nucl. Med., 46, 1028 Lahvis, 2011, Translating mouse vocalizations: prosody and frequency modulation, Genes Brain Behav., 10, 4, 10.1111/j.1601-183X.2010.00603.x Lai, 2014, Assessing schizophrenia-relevant cognitive and social deficits in mice: a selection of mouse behavioral tasks and potential therapeutic compounds, Curr. Pharm. Des. Curr. Pharm. Des., 10.2174/1381612819666140110122750 Lane, 2013, Add-on treatment of benzoate for chizophrenia: a randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor, JAMA Psychiatry, 70, 1267, 10.1001/jamapsychiatry.2013.2159 Lane, 2010, A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia, Int. J. Neuropsychopharmacol., 13, 451, 10.1017/S1461145709990939 Lee, 2012, Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model, Neuron, 75, 714, 10.1016/j.neuron.2012.06.016 Lee, 2012, Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: what have we learnt?, Neurosci. Biobehav. Rev., 36, 556, 10.1016/j.neubiorev.2011.09.001 Lee, 2013, Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind, placebo controlled pilot study, Schizophr. Res., 145, 110, 10.1016/j.schres.2013.01.001 Lee, 2005, Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin, Neuropsychopharmacology, 30, 1883, 10.1038/sj.npp.1300722 Lee, 2007, Prenatal stress generates deficits in rat social behavior: reversal by oxytocin, Brain Res., 1156, 156, 10.1016/j.brainres.2007.04.042 Lee, 2013, Extensive white matter abnormalities in patients with first-episode schizophrenia: a Diffusion Tensor Imaging (DTI) study, Schizophr. Res., 143, 231, 10.1016/j.schres.2012.11.029 Lepage, 2011, Emotional face processing and flat affect in schizophrenia: functional and structural neural correlates, Psychol. Med., 41, 1833, 10.1017/S0033291711000031 Le Pen, 2002, Deficits in reward sensitivity in a neurodevelopmental rat model of schizophrenia, Psychopharmacology, 161, 434, 10.1007/s00213-002-1092-4 Lesh, 2011, Cognitive control deficits in schizophrenia: mechanisms and meaning, Neuropsychopharmacology, 36, 316, 10.1038/npp.2010.156 Leucht, 2004, Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials, Int. J. Neuropsychopharmacol., 7, S15, 10.1017/S1461145704004109 Leucht, 2013, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet, 382, 951, 10.1016/S0140-6736(13)60733-3 Leucht, 2009, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet, 373, 31, 10.1016/S0140-6736(08)61764-X Levkovitz, 2010, A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia, J. Clin. Psychiatry, 71, 138, 10.4088/JCP.08m04666yel Levy, 2006, Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits, Cereb. Cortex, 16, 916, 10.1093/cercor/bhj043 Leweke, 2012, Anandamide dysfunction in prodromal and established psychosis, Curr. Pharm. Des., 18, 5188, 10.2174/138161212802884843 Leweke, 2012, Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Transl. Psychiatry, 2, e94, 10.1038/tp.2012.15 Lewis, 2012, Cortical circuit dysfunction and cognitive deficits in schizophrenia – implications for preemptive interventions, Eur. J. Neurosci., 35, 1871, 10.1111/j.1460-9568.2012.08156.x Li, 2011, D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex, Proc. Natl. Acad. Sci. USA, 108, 12107, 10.1073/pnas.1109718108 Lin, 2013, Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia, Schizophr. Res., 146, 231, 10.1016/j.schres.2013.02.009 Lincoln, 2011, Negative symptoms and social cognition: identifying targets for psychological interventions, Schizophr. Bull., 37, S23, 10.1093/schbul/sbr066 Lindenmayer, 2013, A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities, Schizophr. Res., 147, 241, 10.1016/j.schres.2013.03.019 Liu, 2014, Minocylcine supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial, Schizophr. Res., 10.1016/j.schres.2014.01.011 Liu, 2005, Oxytocin receptors in brain cortical regions are reduced in haploinsufficient (+/−) reeler mice, Neurol. Res., 27, 339, 10.1179/016164105X35602 Loiseau, 2008, Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex, Psychopharmacology, 196, 93, 10.1007/s00213-007-0934-5 Lydall, 2010, Analysis of licking microstructure provides no evidence for a reduction in reward value following acute or sub-chronic phencyclidine administration, Psychopharmacology, 209, 153, 10.1007/s00213-010-1779-x Ma, 2013, Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice, PLoS One, 8, e56053, 10.1371/journal.pone.0056053 Maaswinkel, 2013, Assessing social engagement in heterogeneous groups of zebrafish: a new paradigm for autism-like behavioral responses, PLoS One, 8, e75955, 10.1371/journal.pone.0075955 Maat, 2012, Social cognition and quality of life in schizophrenia, Schizophr. Res., 137, 212, 10.1016/j.schres.2012.02.017 Makris, 2010, White matter volume abnormalities and associations with symptomatology in schizophrenia, Psychiatry Res., 183, 21, 10.1016/j.pscychresns.2010.04.016 Malaspina, 2014, Negative symptoms, past and present: a historical perspective and moving to DSM-5, Eur. Neuropsychopharmacol., 24, 710, 10.1016/j.euroneuro.2013.10.018 Malhotra, 2012, CNVs: Harbingers of a rare variant revolution in psychiatric genetics, Cell, 148, 1223, 10.1016/j.cell.2012.02.039 Manoliu, 2013, Insular dysfunction reflects altered between-network connectivity and severity of negative symptoms in schizophrenia during psychotic remission, Front. Hum. Neurosci., 7, 216, 10.3389/fnhum.2013.00216 Marder, 2014, Defining and measuring negative symptoms of schizophrenia in clinical trials, Eur. Neuropsychopharmacol., 24, 737, 10.1016/j.euroneuro.2013.10.016 Markou, 2013, Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia, Neurosci. Biobehav. Rev., 37, 2149, 10.1016/j.neubiorev.2013.08.007 Marona-Lewicka, 2011, An animal model of schizophrenia based on chronic LSD administration: old idea, new results, Neuropharmacology, 61, 503, 10.1016/j.neuropharm.2011.02.006 Marx, 2011, Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence, Neuroscience, 191, 78, 10.1016/j.neuroscience.2011.06.076 Masi, 2006, Children with schizophrenia: clinical picture and pharmacological treatment, CNS Drugs, 20, 841, 10.2165/00023210-200620100-00005 Matsuoka, 2005, N-1900, an arginine-vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: therapeutic implications for schizophrenia, Brain Res., 1053, 131, 10.1016/j.brainres.2005.06.035 Matsuzawa, 2008, Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study, PLoS One, 3, e1944, 10.1371/journal.pone.0001944 Mazza, 2013, Dysfunctional neuronal networks associated with impaired social interactions in early psychosis: an ICA analysis, Brain Imaging Behav., 7, 248, 10.1007/s11682-013-9223-6 McTighe, 2013, The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex, PLoS One, 8, e62189, 10.1371/journal.pone.0062189 Meffre, 2012, 5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia, EMBO Mol. Med., 4, 1043, 10.1002/emmm.201201410 Mehta, 2013, Social and neuro-cognition as distinct cognitive factors in schizophrenia: a systematic review, Schizophr. Res., 148, 3, 10.1016/j.schres.2013.05.009 Mehta, 2011, Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research, Clin. Psychol. Rev., 31, 161, 10.1016/j.cpr.2010.09.002 Meisenzahl, 2008, Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study, Pharmacopsychiatry, 41, 169, 10.1055/s-2008-1076727 Meltzer, 2012, Serotonergic mechanisms as targets for existing and novel antipsychotics, Handb. Exp. Pharmacol., 212, 87, 10.1007/978-3-642-25761-2_4 Messinger, 2011, Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research, Clin. Psychol. Rev., 31, 161, 10.1016/j.cpr.2010.09.002 Meyer, 2010, Epidemiology-driven neurodevelopmental animal models of schizophrenia, Prog. Neurobiol., 90, 285, 10.1016/j.pneurobio.2009.10.018 Meyer-Lindenberg, 2011, Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine, Nat. Rev. Neurosci., 12, 524, 10.1038/nrn3044 Meyza, 2013, The BTBR T+ tf/J mouse model for autism spectrum disorders-in search of biomarkers, Behav. Brain Res., 251, 25, 10.1016/j.bbr.2012.07.021 Millan, 2005, NMDA receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives, Psychopharmacology, 179, 30, 10.1007/s00213-005-2199-1 Millan, 2006, Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application, Pharmacol. Ther., 110, 135, 10.1016/j.pharmthera.2005.11.006 Millan, 2010, From the cell to the clinic: a comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease, Pharmacol. Ther., 128, 229, 10.1016/j.pharmthera.2010.06.002 Millan, 2013, An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy, Neuropharmacology, 68, 2, 10.1016/j.neuropharm.2012.11.015 Millan, 2012, Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy, Nat. Rev., 11, 141 Millan, 2013, Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative, Neurosci. Biobehav. Rev., 37, 2166, 10.1016/j.neubiorev.2013.09.012 Millan, 2008, Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D3>D2 antagonist, S33138, Therapie, 63, 187, 10.2515/therapie:2008041 Millan, 1999, Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat, Eur. J. Neurosci., 11, 4419, 10.1046/j.1460-9568.1999.00858.x Millan, 2000, J. Pharmacol. Exp. Ther., 292, 54 Millan, 2007, Selective blockade of dopamine D3 vs D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis, J. Neurochem., 100, 1047, 10.1111/j.1471-4159.2006.04262.x Mitchell, 2011, The role of dopamine in symptoms and treatment of apathy in Alzheimer׳s disease, CNS Neurosci. Ther., 17, 411, 10.1111/j.1755-5949.2010.00161.x Miyamoto, 2012, Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents, Mol. Psychiatry, 17, 1206, 10.1038/mp.2012.47 Modabbernia, 2013, Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study, CNS Drugs, 27, 57, 10.1007/s40263-012-0022-1 Möller, 2003, Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality, Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 1101, 10.1016/j.pnpbp.2003.09.006 Montag, 2013, Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study, World J. Psychiatry, 14, 500, 10.3109/15622975.2012.677547 Monte, 2013, Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways, J. Psychopharmacol., 27, 1032, 10.1177/0269881113503506 Morris, 2005, PCP: from pharmacology to modelling schizophrenia, Curr. Opin. Pharmacol., 5, 101, 10.1016/j.coph.2004.08.008 Morris, 2012, Disambiguating ventral striatum fMRI-related BOLD signal during expected reward prediction in schizophrenia, Mol. Psychiatry, 235, 280, 10.1038/mp.2011.75 Morrison, 2014, Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomized controlled trial, Lancet, 42, 1049 Moser, 2014, Evaluating negative-symptom-like behavioural changes in developmental models in schizophrenia, Eur. Neuropsychopharmacol., 24, 774, 10.1016/j.euroneuro.2013.11.004 Mugnaini, 2013, Occupancy of brain dopamine D3 receptors and drug craving: a translational approach, Neuropsychopharmacology, 38, 302, 10.1038/npp.2012.171 Müller, 2013, Anti-inflammatory treatment in schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry, 42, 146, 10.1016/j.pnpbp.2012.11.008 Murai, 2007, Hypofonctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling, Behav. Brain Res., 180, 152, 10.1016/j.bbr.2007.03.003 Murphy, 2006, Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review, Schizophr. Res., 88, 5, 10.1016/j.schres.2006.07.002 Murray, 2013, The drive to strive: goal generation based on current needs, Front. Neurosci., Jun 27, 112 Naber, 2009, The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians, CNS Drugs, 23, 649 Nader, 2012, Social dominance in female monkeys: dopamine receptor functions and cocaine reinforcement, Biol. Psychiatry, 72, 414, 10.1016/j.biopsych.2012.03.002 Nagai, 2011, Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal poly l:C treatment, Behav. Brain Res., 225, 305, 10.1016/j.bbr.2011.07.049 Nagai, 2012, d-serine ameliorates neonatal Poly l:C treatment-induced emotional and cognitive impairments in adult mice, J. Pharmacol. Sci., 120, 213, 10.1254/jphs.12142FP Nakagami, 2008, Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects, Schizophr. Res., 105, 95, 10.1016/j.schres.2008.06.015 Nakajima, 2013, The potential role of dopamine D3 receptor neurotransmission in cognition, Eur. Neuropsychopharmacol., 23, 799, 10.1016/j.euroneuro.2013.05.006 Nakako, 2013, Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets, Behav. Brain Res., 249, 109, 10.1016/j.bbr.2013.04.012 Nakamura, 2013, Gray matter changes in subjects at high risk for developing psychosis and first-episode schizophrenia: a voxel-based structural MRI study, Front. Psychiatry, 4, 16, 10.3389/fpsyt.2013.00016 Nakaya, 2008, A two-factor structure for the schedule for the deficit syndrome in schizophrenia, Psychiatry Res., 158, 256, 10.1016/j.psychres.2007.10.008 Neill, 2010, Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism, Pharmacol. Ther., 128, 419, 10.1016/j.pharmthera.2010.07.004 Neill, 2014, Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans, Eur. Neuropsychopharmacol., 24, 822, 10.1016/j.euroneuro.2013.09.011 Nenadic, 2012, Glutamate receptor δ 1 (GRID1) genetic variation and brain structure in schizophrenia, J. Psychiatr. Res., 46, 1531, 10.1016/j.jpsychires.2012.08.026 Nestor, 2013, Neuropsychological variability, symptoms, and brain imaging in chronic schizophrenia, Brain Imaging Behav., 7, 68, 10.1007/s11682-012-9193-0 Nielsen, 2012, Alterations of the brain reward system in antipsychotic naïve schizophrenia patients, Biol. Psychiatry, 71, 898, 10.1016/j.biopsych.2012.02.007 Nikiforuk, 2013, Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats, PLoS One, 8, e66695, 10.1371/journal.pone.0066695 Noh, 2013, Impaired coupling of local and global functional feedbacks underlies abnormal synchronization and negative symptoms of schizophrenia, BMC Syst. Biol., 7, 30, 10.1186/1752-0509-7-30 Nordentoft, M., Melau, M., Iversen, T., Petersen, L., Jeppesen, P., Thorup, A., Bartelsen, M., Hjorthoj, C.R., Hastrup, L.H., Jorgensen, P., 2014. From research to practice: how OPUS treatment was accepted and implemented throughout Denmark. Early Interv. Psychiatry, 10.1111/eip.12108 Norton, 2013, Toward developmental models of psychiatric disorders in zebrafish, Front. Neural Circuits, 7, 79, 10.3389/fncir.2013.00079 Nuss, 2010, Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride, Curr. Med. Res. Opin., 26, 787, 10.1185/03007990903576953 Oribe, 2013, Early and late stages of visual processing in individuals in prodromal state and first episode schizophrenia: an ERP study, Schizophr. Res., 146, 95, 10.1016/j.schres.2013.01.015 Orliac, 2013, Links among resting-state default-mode network, salience network, and symptomatology in schizophrenia, Schizophr. Res., 148, 74, 10.1016/j.schres.2013.05.007 O׳Tuathaigh, 2007, Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia risk gene neuregulin 1, Neuroscience, 147, 18, 10.1016/j.neuroscience.2007.03.051 O’Tuathaigh, 2014, Genetically modified mice related to schizophrenia and other psychoses: seeking phenotypic insights into the pathobiology and treatment of negative symptoms, Eur. Neuropsychopharmacol., 24, 800, 10.1016/j.euroneuro.2013.08.009 Ozgürdal, 2008, Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia, Schizophr. Res., 105, 272, 10.1016/j.schres.2008.05.017 Padoa-Schioppa, 2011, The orbitofrontal cortex and the computation of subjective value: consolidated concepts and new perspectives, Ann. NY Acad. Sci., 1239, 130, 10.1111/j.1749-6632.2011.06262.x Pallanti, 2004, Social anxiety in outpatients with schizophrenia: a relevant cause of disability, Am. J. Psychiatry, 161, 53, 10.1176/appi.ajp.161.1.53 Papouin, 2012, Synaptic and extrasynaptic NMDA receptors are gated by different endogenous co-agonists, Cell, 150, 633, 10.1016/j.cell.2012.06.029 Park, 2009, Medial prefrontal default-mode hypoactivity affecting trait physical anhedonia in schizophrenia, Psychiatry Res., 171, 155, 10.1016/j.pscychresns.2008.03.010 Peciña, 2010, Hedonic and motivational roles of opioids in food reward: implications for overeating disorders, Pharmacol. Biochem. Behav., 97, 34, 10.1016/j.pbb.2010.05.016 Pedersen, 2011, Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia, Schizophr. Res., 132, 50, 10.1016/j.schres.2011.07.027 Pell, 2011, Modulation of cortical excitability induced by repetitive transcranial magnetic stimulation: influence of timing and geometrical parameters and underlying mechanisms, Prog. Neurobiol., 93, 59, 10.1016/j.pneurobio.2010.10.003 Peralta, 2004, The deficit syndrome of the psychotic illness. A clinical and nosological study, Eur. Arch. Psychiatry Clin. Neurosci., 254, 165, 10.1007/s00406-004-0464-7 Peralta, 2014, Characterisation of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs, Schizophr. Bull., 40, 214, 10.1093/schbul/sbs152 Pietersen, 2007, An animal model of emotional blunting in schizophrenia, PLoS One, 12, e1360, 10.1371/journal.pone.0001360 Pinault, 2011, Dysfunctional thalamus-related networks in schizophrenia, Schizophr. Bull., 37, 238, 10.1093/schbul/sbq165 Piontkewitz, 2012, Tracing the development of psychosis and its prevention: what can be learned from animal models, Neuropharmacology, 62, 1273, 10.1016/j.neuropharm.2011.04.019 Piskutic, 2012, Negative symptoms in individuals at clinical high risk of psychosis, Psychiatry Res., 195, 220, 10.1016/j.psychres.2012.02.018 Pitcher, 2011, Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors, Nat. Med., 17, 470, 10.1038/nm.2315 Pittaras, 2014, Mice gamble for food: individual differences in risky choices and prefrontal cortex serotonin, J. Addict. Res. Ther. Pobbe, 2012, Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors, Horm. Behav., 61, 436, 10.1016/j.yhbeh.2011.10.010 Poeppel, 2012, The maps problem and the mapping problem: two challenges for a cognitive neuroscience of speech and language, Cogn. Neuropsychol., 29, 34, 10.1080/02643294.2012.710600 Poels, 2014, Imaging glutamate in schizophrenia: review of findings and implications for drug discovery, Mol. Psychiatry, 19, 20, 10.1038/mp.2013.136 Potkin, 2002, A PET study of the pathophysiology of negative symptoms in schizophrenia, Am. J. Psychiatry, 159, 227, 10.1176/appi.ajp.159.2.227 Potkin, 2013, Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis, Schizophr. Res., 150, 442, 10.1016/j.schres.2013.08.024 Pratt, 2012, Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap, Nat. Rev. Drug Discov., 11, 560, 10.1038/nrd3649 Prikryl, 2013, Can repetitive transcranial magnetic stimulation be considered effective treatment option for negative symptoms of schizophrenia, J. ECT, 29, 67, 10.1097/YCT.0b013e318270295f Prikryl, 2013, A detailed analysis of the effect of repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: a double-blind trial, Schizophr. Res., 167, 10.1016/j.schres.2013.06.015 Purcell, 2014, A polygenic burden of rare disruptive mutations in schizophrenia, Nature, 506, 185, 10.1038/nature12975 Puri, 2010, Progressive structural brain changes in schizophrenia, Expert Rev. Neurother., 10, 33, 10.1586/ern.09.142 Rapado-Castro, 2010, Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the positive and negative syndrome scale, J. Clin. Psychiatry, 71, 327, 10.4088/JCP.08m04845yel Rapoport, 2012, Neurodevelopmental model of schizophrenia: update 2012, Mol. Psychiatry, 17, 1228, 10.1038/mp.2012.23 Reid, 2010, Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia, Biol. Psychiatry, 68, 625, 10.1016/j.biopsych.2010.04.013 Remington, 2011, Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment, Expert Rev. Neurother., 11, 589, 10.1586/ern.10.191 Ring, 2010, Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist, Neuropharmacology, 58, 69, 10.1016/j.neuropharm.2009.07.016 Ritsner, M.S., Bawakny, H., Kreinin, A., 2014. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized, add-on, two-center trial. Psychiatry Clin. Neurosci. 10.1111/pcn.12150 Ritsner, 2010, Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial, J. Clin. Psychiatry, 71, 1351, 10.4088/JCP.09m05031yel Roder, 2011, Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update, Schizophr. Bull., 37, S71, 10.1093/schbul/sbr072 Romm, 2011, Assessment of social anxiety in first episode psychosis using the Liebowitz Social Anxiety scale as a self-report measure, Eur. Psychiatry, 26, 115, 10.1016/j.eurpsy.2010.08.014 Rosenfeld, 2011, Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia, Schizophr. Bull., 37, 1077, 10.1093/schbul/sbq015 Rowland, 2013, In vivo measurements of glutamate, GABA, and NAAG in schizophrenia, Schizophr. Bull., 39, 1096, 10.1093/schbul/sbs092 Rubin, 2010, Peripheral oxytocin is associated with reduced symptom severity in schizophrenia, Schizophr. Res., 124, 13, 10.1016/j.schres.2010.09.014 Rueter, 2004, Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia, Psychopharmacology, 176, 312, 10.1007/s00213-004-1897-4 Rummel, 2006, Antidepressants for the negative symptoms of schizophrenia, Cochrane Database Syst. Rev., 3, CD005581 Rund, 2009, Is there a degerative process going on in the brain of people with schizophrenia?, Front. Hum. Neurosci., 3, 36, 10.3389/neuro.09.036.2009 Rus-Calafell, 2013, A brief cognitive-behavioural social skills training for stabilised outpatients with schizophrenia: a preliminary study, Schizophr. Res., 143, 327, 10.1016/j.schres.2012.11.014 Rushworth, 2013, Are there specialized circuits for social cognition and are they unique to humans?, Curr. Opin. Neurobiol., 23, 436, 10.1016/j.conb.2012.11.013 Sabbag, 2011, Preventive pharmacological treatment – an evolving new concept in schizophrenia, Isr. J. Psychiatry Relat. Sci., 48, 82 Sacchi, 2013, d-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy, Curr. Pharm. Des., 19, 2499, 10.2174/1381612811319140002 Sala, 2013, Mice heterozygous for the oxytocin receptor gene (Oxtr(+/−)) show impaired social behaviour but not increased aggression or cognitive inflexibility: evidence of a selective haploinsufficiency gene effect, J. Neuroendocrinol., 25, 107, 10.1111/j.1365-2826.2012.02385.x Salamone, 2012, The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond, J. Exp. Anal. Behav., 97, 125, 10.1901/jeab.2012.97-125 Sams-Dodd, 1995, Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats, Behav. Pharmacol., 6, 55, 10.1097/00008877-199501000-00009 Sanchez, 2014, Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial, Schizophr. Bull., 40, 707, 10.1093/schbul/sbt057 Sanfilipo, 2000, Volumetric measures of the frontal and temporal lobe regions in schizophrenia-relationship to negative symptoms, Arch. Gen. Psychiatry, 57, 471, 10.1001/archpsyc.57.5.471 Santiesteban, 2012, Enhancing social ability by stimulating right temporoparietal junction, Curr. Biol., 22, 2274, 10.1016/j.cub.2012.10.018 Sarin, 2011, Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials, Nord. J. Psychiatry, 65, 162, 10.3109/08039488.2011.577188 Sasayama, 2012, Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia, Schizophr. Res., 139, 201, 10.1016/j.schres.2012.06.016 Scattoni, 2013, Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+ tf/J strain, a mouse model of autism, Behav. Brain Res., 251, 35, 10.1016/j.bbr.2012.12.028 Schacter, 2007, Remembering the past to imagine the future: the prospective brain, Nat. Rev. Neurosci., 8, 657, 10.1038/nrn2213 Schobel, 2013, Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver, Neuron, 78, 81, 10.1016/j.neuron.2013.02.011 Schobel, 2009, Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia, Schizophr. Res., 114, 110, 10.1016/j.schres.2009.07.016 Scholsburg, 2013, Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake, J. Neurosci., 33, 19384, 10.1523/JNEUROSCI.1979-13.2013 Schwabe, 2006, Behavioural effects of neonatal lesions of the medial prefrontal cortex and subchronic pubertal treatment with phencyclidine of adult rats, Behav. Brain Res., 168, 150, 10.1016/j.bbr.2005.11.005 Schwarcz, 2012, Kynurenines in the mammalian brain: when physiology meets pathology, Nat. Rev. Neurosci., 13, 465, 10.1038/nrn3257 Scoriels, 2013, Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain, Neuropharmacology, 64, 168, 10.1016/j.neuropharm.2012.07.011 Seibt, 2011, Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio), Behav. Brain Res., 224, 135, 10.1016/j.bbr.2011.05.034 Seillier, 2010, Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats, Int. J. Neuropsychopharmacol., 13, 373, 10.1017/S146114570999023X Seillier, 2013, Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia, Neuropsychopharmacology, 38, 1816, 10.1038/npp.2013.81 Sekimoto, 2011, Cortical regional differences of delta waves during all-night sleep in schizophrenia, Schizophr. Res., 126, 284, 10.1016/j.schres.2010.11.003 Sergi, 2007, Social cognition in schizophrenia: relationships with neurocognition and negative symptoms, Schizophr. Res., 90, 316, 10.1016/j.schres.2006.09.028 Shen, 2014, A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia, J. Psychiatry Res., 53, 14, 10.1016/j.jpsychires.2014.02.012 Shi, 2014, Revisiting the therapeutic effect of rTMS on negative simptoms in schizophrenia: a meta-analysis, Psychiatry Res., 215, 505, 10.1016/j.psychres.2013.12.019 Silver, 2011, SSRI augmentation of antipsychotics alters expression of GABAA receptor and related genes in PMC of schizophrenia patients, Int. J. Neuropsychopharmacol., 14, 573, 10.1017/S1461145710001471 Silverman, 2010, Behavioural phenotyping assays for mouse models of autism, Nat. Rev. Neurosci., 11, 490, 10.1038/nrn2851 Simon, 2010, Neural correlates of reward processing in schizophrenia-relationship to apathy and depression, Schizophr. Res., 118, 154, 10.1016/j.schres.2009.11.007 Simpson, 2011, Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia, Biol. Psychiatry, 69, 928, 10.1016/j.biopsych.2011.01.012 Simpson, E.H., Winiger, V., Biezonski, D.K., Haq, I., Kandel, E.R., Kellendonk, C., 2014. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition Biol. Psychiatry, 10.1016/j.biopsych.2013.11.023 Singh, 2011, Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia, CNS Drugs, 25, 859, 10.2165/11586650-000000000-00000 Singh, 2010, Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis, Br. J. Psychiatry, 197, 174, 10.1192/bjp.bp.109.067710 Smieskova, 2012, Different duration of at-risk mental state associated with neurofunctional abnormalities. A multimodal imaging study, Hum. Brain Mapp., 33, 2281, 10.1002/hbm.21360 Smith, 2007, Maternal immune activation alters fetal brain development through interleukin-6, J. Neurosci., 27, 10695, 10.1523/JNEUROSCI.2178-07.2007 Sommer, 2012, Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review, Schizophr. Bull., 38, 1003, 10.1093/schbul/sbr004 Stan, 2012, Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies, Curr. Pharm. Biotechnol., 13, 1557, 10.2174/138920112800784925 Starkstein, 2009, The syndromal validity and nosological position of apathy in Parkinson’s disease, Mov. Disord., 24, 1211, 10.1002/mds.22577 Stauffer, 2013, Pomaglumetad methionil: no significant difference as an adjuntive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo, Schizophr. Res., 150, 434, 10.1016/j.schres.2013.08.020 Stella, 2014, Neurobiological correlates of apathy in Alzheimer’s disease and mild cognitive impairment: a critical review, J. Alzheimers Dis., 39, 633, 10.3233/JAD-131385 Stip, 2005, Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry, 29, 21, 10.1016/j.pnpbp.2004.08.015 Stratella, 2001, Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus, J. Neurosci., 21, RC157, 10.1523/JNEUROSCI.21-15-j0003.2001 Strauss, 2013, Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome, J. Psychiatr. Res., 47, 783, 10.1016/j.jpsychires.2013.01.015 Strauss, 2012, Next-generation negative symptom assessment for clinical trials: validation of the brief negative symptom scale, Schizophr. Res., 142, 88, 10.1016/j.schres.2012.10.012 Strauss, 2014, A review of reward processing and motivational impairment in schizophrenia, Schizophr. Bull., 40, 5107, 10.1093/schbul/sbt197 Sullivan, 2012, Genetic architectures of psychiatric disorders: the emerging picture and its implications, Nat. Rev. Genet., 13, 537, 10.1038/nrg3240 Suzuki, 2009, Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice, Hum. Mol. Genet., 18, 1652, 10.1093/hmg/ddp086 Takao, 2013, Deficiency of Schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia, Neuropsychopharmacology, 38, 1409, 10.1038/npp.2013.38 Takayanagi, 2013, Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia, Schizophr. Res., 150, 484, 10.1016/j.schres.2013.07.036 Takayanagi, 2010, Volume reduction and altered sulco-gyral pattern of the orbitofrontal cortex in first-episode schizophrenia, Schizophr. Res., 121, 55, 10.1016/j.schres.2010.05.006 Talbot, 2009, The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research, Prog. Brain Res., 179, 87, 10.1016/S0079-6123(09)17910-4 Tandon, 2013, Definition and description of schizophrenia in the DSM-5, Schizophr. Res., 150, 3, 10.1016/j.schres.2013.05.028 Taylor, 2014, Abnormal GABAergic function and negative affect in schizophrenia, Neuropsychopharmacology, 29, 1000, 10.1038/npp.2013.300 Taylor, 2012, Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia, Biol. Psychiatry, 71, 136, 10.1016/j.biopsych.2011.09.007 Thiel, 2008, Social reward-conditioned place preference: a model revealing an interaction between cocaine and social context rewards in rats, Drug Alcohol Depend., 96, 202, 10.1016/j.drugalcdep.2008.02.013 Thoma, 2005, M50 sensory gating predicts negative symptoms in schizophrenia, Schizophr. Res., 73, 311, 10.1016/j.schres.2004.07.001 Treadway, 2009, Worth the EEfRT? The effort expenditure for rewards task as an objective measure of motivation and anhedonia, PLoS One, 4, e6598, 10.1371/journal.pone.0006598 Treadway, 2012, Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia, J. Abnorm. Psychol., 121, 553, 10.1037/a0028813 Trezza, 2008, Cannabinoid and opioid modulation of social play behavior in adolescent rats: differential behavioral mechanisms, Eur. Neuropsychopharmacol., 18, 519, 10.1016/j.euroneuro.2008.03.001 Trezza, 2011, Evaluating the rewarding nature of social interactions in laboratory animals, Dev. Cogn. Neurosci., 1, 444, 10.1016/j.dcn.2011.05.007 Trezza, 2011, Nucleus accumbens μ-opioid receptors mediate social reward, J. Neurosci., 31, 6362, 10.1523/JNEUROSCI.5492-10.2011 Trifilieff, 2013, Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation, Mol. Psychiatry, 18, 1025, 10.1038/mp.2013.57 Tseng, 2009, The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia, Behav. Brain Res., 204, 295, 10.1016/j.bbr.2008.11.039 Turgeon, 2007, Subchronic phencyclidine exposure potentiates the behavioral and c-Fos response to stressful stimuli in rats, Pharmacol. Biochem. Behav., 88, 73, 10.1016/j.pbb.2007.07.005 Tzschentke, 2007, Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade, Addict. Biol., 12, 227, 10.1111/j.1369-1600.2007.00070.x Umbricht, D., Yoo, K., Youssef, E., Dorflinger, E., Martin-Facklam, M., Bausch, A., Arrowsmith, R., Alberati, D., Marder, S.R., Santarelli, L., 2010. Glycine Transporter Type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. In: Proceedings of the ACNP 49th Annual Meeting, Miami Beach, FL. Unschuld, 2014, Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction, Schizophr. Bull., 40, 653, 10.1093/schbul/sbt077 Ursu, 2011, Prefrontal cortical deficits and impaired cognition-emotion interactions in schizophrenia, Am. J. Psychiatry, 168, 276, 10.1176/appi.ajp.2010.09081215 Valencia, 2013, The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia, J. Psychiatr. Res., 47, 1886, 10.1016/j.jpsychires.2013.09.006 Van Veelen, 2010, Left dorsolateral prefrontal cortex dysfunction in medication-naïve schizophrenia, Schizophr. Res., 123, 22, 10.1016/j.schres.2010.07.004 Vardigan, 2010, MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?Pharmacology, Biochem. Behav., 95, 223, 10.1016/j.pbb.2010.01.010 Vázquez-Roque, 2012, Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia, J. Neurosci. Res., 90, 288, 10.1002/jnr.22753 Vazquez-Roque, 2014, Chronic cerebrolysin administration attenuates neuronal abnormalities in the basolateral amygdala induced by neonatal ventral hippocampus lesion in the rat, Synapse, 68, 31, 10.1002/syn.21718 Vita, 2012, Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies, Transl. Psychiatry, 2, e190, 10.1038/tp.2012.116 Ventura, 2009, Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis, Schizophr. Res., 113, 189, 10.1016/j.schres.2009.03.035 Voges, 2005, The association between social anxiety and social functioning in first episode psychosis, Schizophr. Res., 76, 287, 10.1016/j.schres.2005.01.001 Voineskos, 2013, Neuroimaging evidence for the deficit subtype of schizophrenia, JAMA Psychiatry, 70, 472, 10.1001/jamapsychiatry.2013.786 Volpe, 2012, Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry, 37, 264, 10.1016/j.pnpbp.2012.02.003 Von Der Heide, 2013, Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis, Brain, 136, 1692, 10.1093/brain/awt094 Waltz, 2009, Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers, Neuropsychopharmacology, 34, 1567, 10.1038/npp.2008.214 Wang, 2010, Neurophysiological and computational principles of cortical rhythms in cognition, Physiol. Rev., 90, 1195, 10.1152/physrev.00035.2008 Ward, 2009, Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits, Behav. Neurosci., 123, 720, 10.1037/a0016503 Ward, 2011, Modeling motivational deficits in mouse models of schizophrenia: behavior analysis as a guide for neuroscience, Behav. Processes, 87, 149, 10.1016/j.beproc.2011.02.004 Ward, 2012, Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia, Neuropsychopharmacology, 37, 1699, 10.1038/npp.2012.15 Watson, 2012, Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex, Neuropsychopharmacology, 37, 770, 10.1038/npp.2011.254 Weber, 2009, Asenapine, CNS Drugs, 23, 781, 10.2165/11200860-000000000-00000 Weiser, 2012, A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia, J. Clin. Psychiatry, 73, e728, 10.4088/JCP.11m07031 Whitfield-Gabrieli, 2012, Default mode network activity and connectivity in psychopathology, Annu. Rev. Rev. Psychol, 8, 49 Wilson, 2014, Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia, Eur. Neuropsychopharmacol., 24, 759, 10.1016/j.euroneuro.2013.11.008 Winter, 2000, Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists. A link between the glutamatergic and serotonergic hypothesis of schizophrenia, Life Sci., 68, 337, 10.1016/S0024-3205(00)00934-6 Wittchen, 2011, The size and burden of mental disorders and other disorders of the brain in Europe 2010, Eur. Neuropsychopharmacol., 21, 655, 10.1016/j.euroneuro.2011.07.018 Wöhr, 2013, Affective communication in rodents ultrasonic vocalization as a tool for research on emotion and motivation, Cell Tissue Res., 354, 81, 10.1007/s00441-013-1607-9 Wong, 2012, Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice, PLoS One, 7, e51455, 10.1371/journal.pone.0051455 Wykes, 2011, A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes, Am. J. Psychiatry, 168, 472, 10.1176/appi.ajp.2010.10060855 Wynn, 2010, Impaired anticipatory event-related potentials in schizophrenia, Int. J. Psychophysiol., 77, 141, 10.1016/j.ijpsycho.2010.05.009 Yadav, 2012, Deletion of glutamate delta-1 receptor in mouse leads to aberrant emotional and social behaviors, PLoS One, 7, e32969, 10.1371/journal.pone.0032969 Yamasue, 2004, Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study, Psychiatry Res., 131, 195, 10.1016/j.pscychresns.2004.05.004 Yang, 2013, Male mice emit distinct ultrasonic vocalizations when the female leaves the social interaction arena, Front Behav Neurosci., 19, 159 Yao, 2011, Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view, Antioxid. Redox Signal., 15, 201, 10.1089/ars.2010.3603 Yee, 2010, Integrity of emotional and motivational states during the prodromal, first-episode, and chronic phases of schizophrenia, J. Abnorm. Psychol., 119, 71, 10.1037/a0018475 Zakhary, 2011, A behavioral and molecular analysis of ketamine in zebrafish, Synapse, 65, 160, 10.1002/syn.20830 Zec, 1995, Neuropsychology of schizophrenia according to Kraepelin: disorders of volition and executive functioning, Eur. Arch. Psychiatry Clin. Neurosci., 245, 216, 10.1007/BF02191800 Zetzsche, 2008, White matter alterations in schizophrenic patients with pronounced negative sympomatology and with positive family history for schizophrenia, Eur. Arch. Psychiatry Clin. Neurosci., 258, 278, 10.1007/s00406-007-0793-4 Zhang, 2013, Efficacy and safety of individual second-generation vs first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis, Int. J. Neuropsychopharmacol., 16, 1205, 10.1017/S1461145712001277 Zhu, F., Zhang, L., Ding, Y.Q., Zheng, Y., Zhao, J., 2014. Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: implication for a new schizophrenia animal model. Brain Behav. Immun. 10.1016/j.bbi.2014.01.017